Member Info for KUMS

Looking good here.

@ 8.50p today. looks like this could see 9p+ in coming weeks.

We have seen the bottom after recent profit taking. Looking to move back up. Got more today after seeing some biggish buys yesterday.

imo but have no funds to top up.

>>>

has I think 80p target.

now & 25p paid.

Back to 24p paid.

All good now.

10k buyer.buys more.

Another 10k buy, There is 10k buyer today,

Someone picking up 10k shares here & moving up to 3.57%

now. This one should see momentum building & should move up fast.

@ 21.50p as per RNS yesterday which is good to see.

Well done. Given us chance to get more. Opti went from 8 to £1 in 7 months. This one looks to going up that way.

as this could do same as OPTI

whilst out of limelight. Then as news gets closer, it will really pay off.

This will happen rise & fall until next good news. It does throw up bargain with sells for patient ones.

should come soon & we are now looking at 1p+ imo! Added more today!

Joe Wiley, CEO of Amryt Pharma, said: "It has been a tremendously exciting year for the Company. Amryt has made significant progress, both strategically and operationally. A landmark point came in December 2016 when we reached an agreement to in-license the drug, Lojuxta, which treats a rare, life-threatening disorder, HoFH. The agreement has provided us with a cash generative product, with untapped sales potential, as well as a pan-European infrastructure which we can use for other drug assets. Building Lojuxta sales will be a major focus for us over 2017. We also made very good progress with our drug candidates - AP101, a potential treatment for EB, a rare and distressing skin disorder with no approved treatment, and AP102, an earlier stage asset with the potential to treat acromegaly. In December we secured a favourable funding facility from the EIB which will support our continuing development. We have started the new financial year in excellent shape. Very encouragingly, since the year end we have continued to experience strong sales of Lojuxta and this week we announced the commencement of our pivotal trial, EASE. We expect to initiate the first patient imminently and anticipate the results of an interim analysis of this study in EB in early 2018.